Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Interim Analysis of Dara VRD in the Treatment of TE-NDMM Patients with Standard Risk Who Refused to Accept ASCT As First Line in China

Chengcheng Fu, Jing Wang, Song Jin, Lingzhi Yan, Jingjing Shang, Weiqin Yao, Xiaolan Shi, Zhi Yan, Depei Wu

Blood (2024) 144 (Supplement 1): 1997.

https://doi.org/10.1182/blood-2024-209260

Published: 2024

Journal Articles

A First-in-Human Study of CT0590, a Triple Knock-out, Allogeneic CAR T-Cell Therapy Targeting BCMA and NKG2A, in Subjects with Relapsed/Refractory Multiple Myeloma

Chengcheng Fu, Lingzhi Yan, Weiqin Yao, Jingjing Shang, Song Jin, Shuang Yan, Fang Tang, Ziling Zhu, Depei Wu, Ying Li, Nishanthan Rajakumaraswamy, Wei Zheng, Hua Jiang, Zhaohui Liao, Zonghai Li

Blood (2024) 144 (Supplement 1): 4843.

https://doi.org/10.1182/blood-2024-204401

Published: 2024

Journal Articles

5-Year Follow-up of Combined Infusion of Anti-CD19 and Anti-BCMA CAR-T after ASCT for High-Risk Newly Diagnosed Multiple Myeloma

Xiaolan Shi, Chengcheng Fu, Lingzhi Yan, Yingying Zhai, Zhi Yan, Jingjing Shang, Song Jin, Xingyue Wu, Hongying You, Shuang Yan, Weiqin Yao, Liqing Kang, Lei Yu, Depei Wu

Blood (2024) 144 (Supplement 1): 4766.

https://doi.org/10.1182/blood-2024-207687

Published: 2024

Journal Articles

Low Intensity Daratumumab to Treat Rersistent/Recurrent Minimal Residual Disease in Multiple Myeloma

Lingzhi Yan, Xiaolan Shi, Jing Wang, Song Jin, Ying Yao, Panfeng Wang, Jingjing Shang, Yingying Zhai, Shuang Yan, Yun Xu, Jiajia Meng, Weiqin Yao, Xiao Ma, Chengcheng Fu, Depei Wu

Blood (2024) 144 (Supplement 1): 4750.

https://doi.org/10.1182/blood-2024-205595

Published: 2024

Journal Articles

MRD Evaluation in a Transplant-Eligible NDMM Study

Yuhe Peng, Chengcheng Fu, Song Jin, Jingjing Shang, Weiqin Yao, Zhi Yan, Yingying Zhai, Li Yao, Hongmiao Shen, Xingyue Wu, Hongying You, Yue Huang, Jing Wang, Jiao Lu, Depei Wu

Blood (2024) 144 (Supplement 1): 6995.

https://doi.org/10.1182/blood-2024-207983

Published: 2024

Journal Articles

Real World Analysis of the Efficacy, Prognosis and Safety of Daratumumab, Carfilzomib, and Dexamethasone (DKD) in Relapsed or Refractory Multiple Myeloma Patients

Chengcheng Fu, Hongying You, Song Jin, Panfeng Wang, Lingzhi Yan, Liying Zhang, Tingting Lu, Xiao Gao, Lei Jiang, Hongchun Qiu, Jingjing Shang, Yingying Zhai, Weiqin Yao, Shuang Yan, Zhi Yan, Depei Wu

Blood (2024) 144 (Supplement 1): 6992.

https://doi.org/10.1182/blood-2024-210102

Published: 2024

Journal Articles

Ixazomib Based Regimens As Front-Line Treatment in Newly Diagnosed Multiple Myeloma Patients in China: A Real-World Data from Infinite Study

Fu Cheng Cheng, Song Jin, Junling Zhuang, Xin Zhou, Fan Zhou, Yuhua Li, Kaiyang Ding, Ting Niu, Wenming Chen, Baijun Fang, Li-Li Chen, Rong Fu, Hao Zhang, Jiaping Fu, Xiuju Wang, Sha Liu, Lin Li, Depei Wu

Blood (2024) 144 (Supplement 1): 6970.

https://doi.org/10.1182/blood-2024-204366

Published: 2024

Journal Articles

11q Gain with t(11;14) or Alone Were Associated with Poor Prognosis in Newly-Diagnosed Multiple Myeloma Patients By SNP-Array Analysis and FISH

Blood (2023) 142 (Supplement 1): 1968.

https://doi.org/10.1182/blood-2023-184870

Published: 2023

Journal Articles

Efficacy and Safety of Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma with Renal Insufficiency in Real-World: A Non-Interventional Prospective Multicenter Observational Study

Chengcheng Fu, Jing Wang, Lingzhi Yan, Song Jin, Jingjing Shang, Xiaolan Shi, Weiqin Yao, Zhi Yan, Mingqing Zhu, De-Pei Wu

Blood (2023) 142 (Supplement 1): 6691.

https://doi.org/10.1182/blood-2023-185362

Published: 2023

Journal Articles

Speckle Tracking Echocardiography for the Diagnosis and Prognosis of Light Chain Cardiac Amyloidosis

Hongmiao Shen, Chengcheng Fu, Xingyue Wu, Hongying You, Zhi Yan, Weiqin Yao, Jiao Lu, Yingying Zhai, Jing Wang, Xiaolan Shi, Shuang Yan, Jingjing Shang, Song Jin, Lingzhi Yan, De-Pei Wu

Blood (2023) 142 (Supplement 1): 6743.

https://doi.org/10.1182/blood-2023-185767

Published: 2023

Journal Articles

CNVs Numbers Scoring System Was a Good Prognostic Risk Stratification for NDMM with Whole Genomic Mapping Array

Zhao Zeng, Chengcheng Fu, Jinlan Pan, Jiao Lu, Jingjing Shang, Zhiyu Zhang, Hongying You, Wanhui Yan, Chunxiao Wu, Qinrong Wang, Qian Wang, Lijun Wen, Song Jin, Lingzhi Yan, Suning Chen, De-pei Wu

Blood (2023) 142 (Supplement 1): 4725.

https://doi.org/10.1182/blood-2023-184504

Published: 2023

Journal Articles

Selinexor, Daratumumab and Dexamethasone for Patients with Multiple Myeloma Previously Treated with Lenalidomide at First Relapse: A Real-World Study

Yingying Zhai, Lingzhi Yan, Song Jin, Jingjing Shang, Xiaolan Shi, Weiqin Yao, Zhi Yan, Shuang Yan, De-pei Wu, Chengcheng Fu

Blood (2023) 142 (Supplement 1): 6739.

https://doi.org/10.1182/blood-2023-185540

Published: 2023

Journal Articles

Initial Safety and Efficacy of Daratumumab (DARA) in Combination with Bortezomib, Lenalidomide, and Dexamethasone in the Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE-NDMM) Patients with Standard Risk Who Refused to Accept ASCT As First Line in China

Chengcheng Fu, Jing Wang, Lingzhi Yan, Song Jin, Jingjing Shang, Xiaolan Shi, Weiqin Yao, Zhi Yan, De-Pei Wu

Blood (2023) 142 (Supplement 1): 6736.

https://doi.org/10.1182/blood-2023-185263

Published: 2023

Journal Articles

IMWG /ECOG Frailty Score Was a Good Indicator for ASCT Candidate Selection for NDMM in China from a Hcmmd Retrospective Study

Xingyue Wu, Chengcheng Fu, Hongmiao Shen, Hongying You, Yingying Zhai, Jing Wang, Zhi Yan, Shuang Yan, Weiqin Yao, Jiao Lu, Jingjing Shang, Song Jin, Xiaolan Shi, Lingzhi Yan, De-Pei Wu

Blood (2023) 142 (Supplement 1): 7061.

https://doi.org/10.1182/blood-2023-185763

Published: 2023

Journal Articles

The Independent Adverse Prognostic Significance of 1q21 Gain/Amplification in Newly Diagnosed Multiple Myeloma Patients

Hongying You, Song Jin, Chunxiao Wu, Qingqing Wang, Shuang Yan, Yingying Zhai, Weiqin Yao, Xiaolan Shi, Jingjing Shang, Lingzhi Yan, Ying Yao, Jing Wang, Panfeng Wang, Jinlan Pan, Depei Wu, Chengcheng Fu

Blood (2022) 140 (Supplement 1): 10056–10057.

https://doi.org/10.1182/blood-2022-159067

Published: 2022

Journal Articles

TP53 Gene Deletion or Mutation in Newly Diagnosed Multiple Myeloma Patients By FISH with Cytoscan Arrays and Targeted Panel Sequencing

Hongying You, Hongjie Shen, Song Jin, Qingqing Wang, Shuang Yan, Yingying Zhai, Weiqin Yao, Xiaolan Shi, Jingjing Shang, Lingzhi Yan, Ying Yao, Jing Wang, Panfeng Wang, Jinlan Pan, Depei Wu, Chengcheng Fu

Blood (2022) 140 (Supplement 1): 4325–4327.

https://doi.org/10.1182/blood-2022-159272

Published: 2022

Journal Articles

Comparison of Next-Generation Flow Cytometry (NGF) and Next-Generation Sequencing (NGS) in the Assessment of Minimal Residual Disease in Multiple Myeloma

Qingqing Wang, Li Yao, Mingqing Zhu, Lingzhi Yan, Song Jin, Jingjing Shang, Xiaolan Shi, Yingying Zhai, Shuang Yan, Weiqin Yao, You Hongying, Depei Wu, Chengcheng Fu

Blood (2022) 140 (Supplement 1): 7249–7250.

https://doi.org/10.1182/blood-2022-157270

Published: 2022

Journal Articles

Phase 2 Suzhou MM02 Study: Chidamide with VRD Versus VRD in Newly Diagnosed High Risk Transplant Eligible Multiple Myeloma Patients

Weiqin Yao, Lingzhi Yan, Jingjing Shang, Song Jin, Xiaolan Shi, Shuang Yan, Depei Wu, Chengcheng Fu

Blood (2021) 138 (Supplement 1): 4765.

https://doi.org/10.1182/blood-2021-152390

Published: 2021

Journal Articles

Targeting 1q21 Amplification with APG2575 and Lenalidomide to Sensitize BCL-2 Inhibition with the Decrease of MCL-1 Protein in High Risk MM Models

Yan Xie, MD, Chengcheng FU, MD PhD, Lingzhi Yan, MD PhD, Song Jin, MD, Jingjing Shang, MD, Xiaolan Shi, MD PhD, Jinlan Pan, MD, Yan Yin, MS, Tingting Mao, MS, Jing Deng, PhD, Douglas D. Fang, MD PhD, Dajun Yang, MD PhD, Yifan Zhai, MD PhD, Shuang Yan, MD, Yingying Zhai, MD, Ying Yao, MD, Panfeng Wang, MD, Jing Wang, MD, Depei Wu, MDPhD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-139195

Published: 2020

Journal Articles

Sequential CD19- and Bcma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study

Lingzhi Yan, Zhi Yan, Jingjing Shang, Xiaolan Shi, Song Jin, Liqing Kang, Su Qu, Jin Zhou, Huizhu Kang, Ruju Wang, Ying Yao, Jing Wang, Weiqin Yao, Guanghua Chen, Lei Yu, Depei Wu, MD PhD, Fu Cheng Cheng, MD PhD

Blood (2019) 134 (Supplement_1): 578.

https://doi.org/10.1182/blood-2019-129740

Published: 2019

NARROW

Interim Analysis of Dara VRD in the Treatment of TE-NDMM Patients with Standard Risk Who Refused to Accept ASCT As First Line in China

A First-in-Human Study of CT0590, a Triple Knock-out, Allogeneic CAR T-Cell Therapy Targeting BCMA and NKG2A, in Subjects with Relapsed/Refractory Multiple Myeloma

5-Year Follow-up of Combined Infusion of Anti-CD19 and Anti-BCMA CAR-T after ASCT for High-Risk Newly Diagnosed Multiple Myeloma

Low Intensity Daratumumab to Treat Rersistent/Recurrent Minimal Residual Disease in Multiple Myeloma

MRD Evaluation in a Transplant-Eligible NDMM Study

Real World Analysis of the Efficacy, Prognosis and Safety of Daratumumab, Carfilzomib, and Dexamethasone (DKD) in Relapsed or Refractory Multiple Myeloma Patients

Ixazomib Based Regimens As Front-Line Treatment in Newly Diagnosed Multiple Myeloma Patients in China: A Real-World Data from Infinite Study

11q Gain with t(11;14) or Alone Were Associated with Poor Prognosis in Newly-Diagnosed Multiple Myeloma Patients By SNP-Array Analysis and FISH

Efficacy and Safety of Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma with Renal Insufficiency in Real-World: A Non-Interventional Prospective Multicenter Observational Study

Speckle Tracking Echocardiography for the Diagnosis and Prognosis of Light Chain Cardiac Amyloidosis

CNVs Numbers Scoring System Was a Good Prognostic Risk Stratification for NDMM with Whole Genomic Mapping Array

Selinexor, Daratumumab and Dexamethasone for Patients with Multiple Myeloma Previously Treated with Lenalidomide at First Relapse: A Real-World Study

Initial Safety and Efficacy of Daratumumab (DARA) in Combination with Bortezomib, Lenalidomide, and Dexamethasone in the Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE-NDMM) Patients with Standard Risk Who Refused to Accept ASCT As First Line in China

IMWG /ECOG Frailty Score Was a Good Indicator for ASCT Candidate Selection for NDMM in China from a Hcmmd Retrospective Study

The Independent Adverse Prognostic Significance of 1q21 Gain/Amplification in Newly Diagnosed Multiple Myeloma Patients

TP53 Gene Deletion or Mutation in Newly Diagnosed Multiple Myeloma Patients By FISH with Cytoscan Arrays and Targeted Panel Sequencing

Comparison of Next-Generation Flow Cytometry (NGF) and Next-Generation Sequencing (NGS) in the Assessment of Minimal Residual Disease in Multiple Myeloma

Phase 2 Suzhou MM02 Study: Chidamide with VRD Versus VRD in Newly Diagnosed High Risk Transplant Eligible Multiple Myeloma Patients

Targeting 1q21 Amplification with APG2575 and Lenalidomide to Sensitize BCL-2 Inhibition with the Decrease of MCL-1 Protein in High Risk MM Models

Sequential CD19- and Bcma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only